Pyridostigmine Bromide - Uses, Dosage and Side Effects

Pyridostigmine is a parasympathomimetic and a reversible cholinesterase inhibitor.
Pyridostigmine inhibits acetylcholinesterase in the synaptic cleft, thus slowing down the hydrolysis of acetylcholine. It is a quaternary carbamate inhibitor of cholinesterase that does not cross the blood-brain barrier, and is taken daily in anticipation of an attack, which carbamylates about 30% of peripheral cholinesterase enzyme. The carbamylated enzyme eventually regenerates by natural hydrolysis and excess ACh levels revert to normal.
Pyridostigmine is used to treat muscle weakness in people with myasthenia gravis and to combat the effects of curariform drug toxicity. Pyridostigmine is now also used to treat orthostatic hypotension.

Pyridostigmine Bromide - Availability And Packaging

Pyridostigmine Bromide is available as Generic Mestinon Tablets which is packaged in tablets of 60 mg. Pyridostigmine bromide is available under the trade names Mestinon (Valeant Pharmaceuticals), Regonol and Distinon (Samarth Pharma, India).

Pyridostigmine Bromide (Generic Mestinon)- Contraindications

Pyrostigmine bromide is contraindicated in cases of mechanical intestinal or urinary obstruction and should be used with caution in patients with bronchial asthma.

Side Effects of Pyridostigmine Bromide (Generic Mestinon)

Common side effects of Generic Mestinon include Sweating, Diarrhea, Nausea Vomiting, Abdominal cramps, Increased salivation, Tearing, Increased bronchial secretions, Constricted pupils, Facial flushing due to vasodilation and Erectile dysfunction.

Pyridostigmine Bromide (Generic Mestinon) - Dosage

The size and frequency of the dosage must be individualized to the meet the needs of the individual patient.
The average dose of Generic Mestinon is ten 60 mg tablets daily which is spaced to provide maximum relief.

Additional Information

Additional Info: Prescribing Information



Considerable portions of the text here is from http://en.wikipedia.org/wiki/Pyridostigmine and is reproduced here under the Creative Commons Attribution-ShareAlike License